Strides Pharma Global Pte. Singapore, a step‐down wholly owned subsidiary, has received approval for Lidocaine Ointment USP 5% from the USFDA.
Share price of Strides Pharma Science gained 3.2 percent in the early trade on Thursday after it received approval for Lidocaine Ointment from
the United States Food & Drug Administration (USFDA).
Strides Pharma Global Pte. Singapore, a step‐down wholly owned subsidiary, has received approval for Lidocaine Ointment USP 5% from the
USFDA.
Lidocaine Ointment is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP.
The product will be marketed by Strides Pharma Inc. in the US market and will be launched immediately.
The company has 80 cumulative ANDA filings with USFDA of which 54 ANDAs have been approved as of date and 26 are pending approval.
At 09:24 hrs Strides Pharma Science was quoting at Rs 474, up Rs 10.70, or 2.31 percent on the BSE.
WhatsApp us